Therapeutic molecules
The present invention relates to effective pain therapies in companion animals. In particular, an isolated companion animal p75NTR protein or a fusion protein containing the same or portions thereof are contemplated. Nucleic acids encoding the proteins are also encompassed in the invention as well as methods of using the same.
1. A fusion protein comprising an extracellular domain of a companion animal p75 neurotrophin receptor protein and a half-life extending moiety; wherein, the fusion protein comprises SEQ ID NO: 11 or 13.
2. A fusion protein according to claim 1 wherein the half-life extending moiety is an Fc domain, a serum albumin binder or PEG.
3. A fusion protein according to claim 2 wherein the half-life extending moiety is a wild type or mutant Fc domain.
4. A fusion protein according to claim 1 wherein the half-life extending moiety is an Fc domain and the p75NTR extracellular domain or portion thereof and the Fc domain are linked with a linker.
5. A fusion protein according to claim 4 wherein the linker is a peptide linker optionally where the peptide linker is (G 4 S) n (SEQ ID NO: 38) wherein n is 1 to 4.
6. A fusion protein according to claim 1 wherein the companion animal is a cat, dog, cow or horse.
7. A pharmaceutical composition comprising the fusion protein according to claim 1 .
8. A method for treating a nerve growth factor NGF-related disorder in a companion animal comprising administering an effective amount of the fusion protein according to claim 1 .
9. The method of claim 8 wherein the NGF-related disorder is cardiovascular disease, atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, pain and inflammation.
10. The method of claim 9 wherein the NGF-related disorder is a pain related disorder.
11. The method of claim 10 wherein the pain is selected from osteoarthritis pain, rheumatoid arthritis pain, surgical and postsurgical pain, incisional pain, general inflammatory pain, cancer pain, pain from trauma, neuropathic pain, neuralgia, diabetic neuropathy pain, pain associated with rheumatic diseases, pain associated with musculoskeletal diseases, visceral pain, and gastrointestinal pain.
12. The method according to claim 9 comprising administration of a second compound that treats pain.